Melinta Therapeutics names Sanfilippo its interim CEO

Melinta Therapeutics Inc., a commercial stage antibiotics company, announced Tuesday it has named Jennifer Sanfilippo as interim CEO and director, effective Aug. 28.

The Morristown-based company said Sanfilippo previously served as senior vice president and general counsel.

“Jennifer’s appointment to interim chief executive officer is the result of a thoughtful succession planning process undertaken by the board of directors. Jennifer is also an ideal addition to Melinta’s board of directors and we are pleased that the board and organization will continue to benefit from her extensive leadership skills, proven track record and hands-on experience in the antibiotics sector within her new roles,” David Gill, chairman of Melinta, said.

Prior to Melinta, Sanfilippo held a number of leadership roles at The Medicines Co.

“I am honored to serve as interim chief executive officer and to join Melinta’s board of directors. I look forward to working closely with the Board, management team and all of our employees as we remain focused on the Company’s strategy to best position Melinta for its next phase,” Sanfilippo said. “The board and I are fully committed to ensuring a smooth transition as we continue to advance Melinta’s mission to provide both patients and physicians with potentially life-saving therapeutic solutions that address the evolving global threat of bacterial infections and antibiotic resistance.”